PR Newswire TechnologyCodex · 实盘不做把握 8/10
北京时间·🕒 发布 02:50:00时区推断·⟳ 抓取 02:52:18·⚡ 决策 07-11 02:53:22 +1m04s·108.7 天前
律师事务所发布 Zoetis 证券集体诉讼征集提醒，未提供新的公司经营或监管事实
这是一则律师事务所的原告征集广告，核心内容是提醒投资者在 2026-07-27 前申请牵头原告，并非新的监管处罚、公司披露或经营数据。
📄 原文PR Newswire Technology↗ 原文
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, July 10, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have…
不做 Zoetis（ZTS.US）
律师事务所原告征集广告不是新的实质负面事件，缺乏可量化增量和足够强的做空催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-10 · 扩散 low · price-in 风险 medium ↗
关键理由
- 这是一则律师事务所的原告征集广告，核心内容是提醒投资者在 2026-07-27 前申请牵头原告，并非新的监管处罚、公司披露或经营数据。
- 正文引用的 Librela、Simparica Trio、Apoquel/Cytopoint 市占率和安全警示问题属于诉讼指控摘要，本条信号本身没有新增可量化业绩冲击。
- 事件方向偏负面但催化强度不足，且做空需要明确强空催化与可借券确认，本条不满足开空红线。
主要风险
- 若后续出现法院实质进展、FDA 新动作或公司更新指引，才可能形成新的可交易事件。
原文全文
展开原文 · 2,503 字
LOS ANGELES, July 10, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS).
IF YOU SUFFERED A LOSS ON YOUR ZOETIS INVESTMENTS, CLICK HERE BEFORE JULY 27, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between January 14, 2025 and May 6, 2026, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
SOURCE Glancy Prongay Wolke & Rotter LLP
IF YOU SUFFERED A LOSS ON YOUR ZOETIS INVESTMENTS, CLICK HERE BEFORE JULY 27, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between January 14, 2025 and May 6, 2026, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
SOURCE Glancy Prongay Wolke & Rotter LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。